Phase lb study of LEE011 and BYL719 in combination with letrozole in estrogen receptor-positive, HER2-negative breast cancer (ER+, HER2− BC).
Year: 2014
Type: conference-abstract
Source: Journal of Clinical Oncology
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: ribociclib, alpelisib, letrozole, estrogen receptor-positive breast cancer, HER2-negative breast cancer, CDK4/6 inhibitors, PI3K inhibitors, aromatase inhibitor resistance, endocrine therapy resistance, combination therapy, dose-limiting toxicity, maximum tolerated dose, pharmacokinetics, postmenopausal women, metastatic breast cancer
Open Access status: closed
OpenAlex ID: W1470988277
